Navigation Links
Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
Date:6/27/2008

KENILWORTH and WHITEHOUSE STATION, N.J., June 27 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) announce the withdrawal of the New Drug Application (NDA) for the loratadine/montelukast combination tablet.

The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture, which was formed in May 2000 to develop and market a fixed-combination product that would combine loratadine and montelukast. This action has no impact on the business of the Merck/Schering-Plough cholesterol joint venture.

The U.S. Food and Drug Administration (FDA) issued on April 25, 2008 a not-approvable letter for the proposed fixed-dose combination of loratadine and montelukast.

As a result of the termination of the respiratory joint venture, Schering- Plough expects to receive payments totaling $105 million from Merck as specified in the joint venture agreements which Schering-Plough will recognize over the remaining three quarters of 2008.


'/>"/>
SOURCE Schering-Plough Corp.; Merck & Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
2. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
3. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
4. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
5. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
7. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
8. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
9. Schering-Plough CEO to Buy $2 Million in Common Shares
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 2017 , ... Veteran Theresa James awoke to the sound of her newly ... “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were violently ... and situations throughout my divorce,” James said. “After the death of my children, I ...
(Date:4/24/2017)... ... ... My T Chai, a South African company that creates a number of ... a popular website specializing in sales of nutritional products. , Chai tea is ... It spread across Asia and Africa quickly, and today recipes vary from region to ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... ... 2017 , ... As a former supermodel known for her timeless beauty, Joan ... single women is that she put all the words in her new book, "Manifest ... personal experiences and sparkling sense of humor have inspired her to write a book ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... shows that over the last decade, student well-being has seriously declined. "When disenfranchised ... of formal education, join the Islamic State to turn the historic multi-ethnic and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
Breaking Medicine Technology: